Skip to main content
SpringerLink
Log in

Plasmapheresis in Neurological Disorder

  • Chapter
Advances in haemapheresis

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 25))

  • 47 Accesses

Abstract

Over the past thirteen years, plasmapheresis, or plasma exchange (PE) has significantly contributed to the understanding and therapy of various neurological disorders where autoimmunity is presumed to play a role. Based on the therapeutic PE (TPE) market research and review of literature 200,000 TPEs were performed worldwide during 1987, one half of which were on patients with neurological disorders. PE however should still be regarded as “primitive”, its development being hindered by our lack of knowledge about its mechanisms of action.Identification and specific removal of the pathogenic molecules from the circulation will not only enhance its therapeutic benefits but will also make PE less expensive.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Consensus Conference. The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986;256:1333–7.

    Article  Google Scholar 

  2. Pinching AJ, Peters KD, Newson-Davis J. Remission of myasthenia gravis following plasma exchange. Lancet 1976;ii:1373–6.

    Article  Google Scholar 

  3. Dau PC, Lindstrom JM, Cassel CK, et al. Plasmapheresis and immunosupressive drug therapy in myasthenia gravis. N Engl J Med 1977;297:1134–40.

    Article  CAS  PubMed  Google Scholar 

  4. Pollard JD, Basten A, Hassall JE, et al. Current trends in the management of myasthenia gravis: Plasmapheresis and immunosupressive therapy. Aust N Z J Med 1989;10:212–7.

    Article  Google Scholar 

  5. Kornfeld, Ambinder EP, Mittag T, et al. Plasmapheresis in refractory generalized myasthenia gravis. Arch Neurol 1981;38:478–81.

    Article  CAS  PubMed  Google Scholar 

  6. Tindall RSA. Scientific overview of myasthenia gravis and an assessment of the role of plasmapheresis. In: Tindall RSA (ed). Therapeutic apheresis and plasma perfusion. New York: Alan R Liss, Inc, 1982:113–42.

    Google Scholar 

  7. Thorlacius S, Lefvert AK, Aarli JA, et al. Plasma exchange in myasthenia gravis: Effect on anti-Ach R antibodies and other autoantibodies. Acta Neurol Scand 1986;74:486–90.

    Article  CAS  PubMed  Google Scholar 

  8. Newsom-Davis J, Wilson SG, Vincent A, et al. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979;i:464–8.

    Article  Google Scholar 

  9. Fennell DF, Ringel SP. Myasthenia gravis and pregnancy. Obstet Gynecol Survey 1987;41:414–21.

    Article  Google Scholar 

  10. Levine SE, Keesey JC. Successful plasmapheresis for fulminant myasthenia gravis during pregnancy. Arch Neurol 1986;43:197–8.

    Article  CAS  PubMed  Google Scholar 

  11. Snijders MPML, de Graaff J, Op de Coul AAW. Myasthenia gravis en zwangerschap. Ned Tijdschr Geneesk 1987;131:1225–7.

    CAS  Google Scholar 

  12. Brettle RP. Gross M, Legg NJ, et al. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978;ii:1100.

    Article  Google Scholar 

  13. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096–104.

    Article  Google Scholar 

  14. Osterman PG, Lundemo G, Priskanen R, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;ii: 1296–9.

    Article  Google Scholar 

  15. French Cooperative Group on Plasma Exchange and Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann Neurol 1987;22:753–61.

    Article  Google Scholar 

  16. Server AC, Lefkowith J, Braine H, et al. Treatment of chronic relapsing inflammatory polyradiculopathy by plasma exchange. Ann Neurol 1979;6: 258–61.

    Article  CAS  PubMed  Google Scholar 

  17. Fowler H, Vulpe M, Marks G, et al. Recovery from chronic progressive polyneuropathy after treatment with plasma exchange and cyclophosphamide. Lancet 1979;ii:1193.

    Article  Google Scholar 

  18. Levy RL, Newkirk R, Ochoa J. Treatment of chronic relapsing Guillain-Barré syndrome by plasma exchange. Lancet 1979;ii:741.

    Article  Google Scholar 

  19. Maas AIR, Busch HFM, van der Heul C. Plasma infusion and plasma exchange in chronic idiopathic polyneuropathy. N Engl J Med 1981;305:344.

    CAS  PubMed  Google Scholar 

  20. Gross MLP, Thomas PK. The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sci 1981;52:69–78.

    Article  CAS  PubMed  Google Scholar 

  21. Toyka KV, Augspach R, Wietholder H, et al. Plasma exchange in chronic inflammatory polyneuropathy: Evidence suggestive of a pathogenic humoral factor. Muscle Nerve 1982;5:479–84.

    Article  CAS  PubMed  Google Scholar 

  22. Van Nuren SA, Gatenby PA, Pollard JD, et al. Specificity of plasma-pheresis in the treatment of chronic relapsing polyneuropathy. Aust N Z J Med 1982;12:81–4.

    Article  Google Scholar 

  23. Tindall RSA. The role of therapeutic apheresis in acute, relapsing, and chronic inflammatory polyneuropathy. In: Tindall RSA (ed). Therapeutic apheresis and plasma perfusion. New York: Alan R Liss, Inc, 1982:205– 22.

    Google Scholar 

  24. Dyck PJ, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461–5.

    Article  CAS  PubMed  Google Scholar 

  25. Feix JNB, Khatri BO, McQuillen MP, Koethe S. Immune reactivity against membranes containing ganglioside GM in chronic progressive multiple sclerosis: Observation by spin-membrane immuno assay. Immunol Comm 1984;13:465–74.

    CAS  Google Scholar 

  26. Endo T, Scott DD, Stewart SS, et al. Antobodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol 1984;132:1793–7.

    CAS  PubMed  Google Scholar 

  27. Garcia-Merino A, Persson MAA, Ernerudh J, et al. Serum and cerebrospinal fluid antibodies against myelin basic protein and their IgG subclass dis- tribution in multiple sclerosis. J Neurol Neurosurg Psychiat 1986;49: 1066–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Huddlestone JR, Oldstone MBA. T-suppressor lymphocytes fluctuate in parallel with changes in the clinical course of patients with multiple sclerosis. J Immunol 1979;123:1616–8.

    Google Scholar 

  29. Reinherz EL, Weiner HL, Hauser SL, et al. Loss of suppressor T cells in active multiple sclerosis. N Engl J Med 1989;303:125–9.

    Article  Google Scholar 

  30. Khatri BO, Koethe S, Mezra K, McQuillen MP. Clinical significance of chronic progressive MS patients undergoing plasmapheresis and immuno-suppressive drug therapy. Soc Neurosci 1981;7:568.

    Google Scholar 

  31. Waksman BH. Rationales of current therapies for multiple sclerosis. Arch Neurol 1983;40:671–2.

    Article  CAS  PubMed  Google Scholar 

  32. Waksman BH, Reynolds WE. Multiple sclerosis as a disease of immune regulation. Proc Soc Exp Biol Med 1984;175:282–94.

    Article  CAS  PubMed  Google Scholar 

  33. Dau PC, Petajan JM, Johnson KP, Panitch HS, Bornstein MB. Plasmapheresis and immunosuppressive drug therapy in multiple sclerosis. Neurology 1980;30:1023–8.

    Article  CAS  PubMed  Google Scholar 

  34. Weiner HL, Dawson DM. Plasmapheresis in multiple sclerosis: Preliminary study. Neurology 1980;30:1029–33.

    Article  CAS  PubMed  Google Scholar 

  35. Khatri BO, McQuillen MP, Koethe SM, Hussey C, Cook A. Plasmapheresis in multiple sclerosis: Correlation of clinical improvement with increased suppressor cell activity in peripheral blood. Trans Am Neurol Assoc 1980;105:318–20.

    Google Scholar 

  36. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: A randomised three-arm study of high-dose intravenous cyclophosphamide, plasma eschange, and ACTH. N Engl J Med 1983;308:173–80.

    Article  CAS  PubMed  Google Scholar 

  37. Khatri BO, Koethe SM, McQuillen MP. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis: A pilot study. Arch Neurol 1984;41:734–8.

    Article  CAS  PubMed  Google Scholar 

  38. Tindall RSA, Walker JE, Ehle AL, et al. Plasmapheresis in multiple sclerosis: Prospective trial of pheresis and immunosuppression versus immu- nosuppression alone. Neurology 1982;32:739–43.

    Article  CAS  PubMed  Google Scholar 

  39. Weiner HL, Dau P, Birnbaum G, et al. Plasma exchange in acute multiple sclerosis: Design of a cooperative study. Arch Neurol 1983;40:691–2.

    Article  CAS  PubMed  Google Scholar 

  40. Guarnieri BM, Capparell R, Fratiglioni L, et al. Plasma exchange in multiple sclerosis. Int J Artif Organs 1985;8:215–20.

    CAS  PubMed  Google Scholar 

  41. Miller RG, Filler Katz A, Kiprov DD. More on plasmapheresis in chronic progressive multiple sclerosis. Neurology 1985;35:1261.

    Article  CAS  PubMed  Google Scholar 

  42. Khatri BI, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patient taking immunosuppressive drugs. Neurology 1985;35:312–9.

    Article  CAS  PubMed  Google Scholar 

  43. Gordon PA, Carroll DJ, Etches WS, et al. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci 1985;12:39–44.

    CAS  PubMed  Google Scholar 

  44. Valbonesi M, Garelli S, Mosconi L, Zerbi D, Forlani G. Plasma exchange in the management of patients with multiple sclerosis: Preliminary observations. Vox Sang 1981;41:68–73.

    Article  CAS  PubMed  Google Scholar 

  45. Höcker P, Stellamor V, Summer K, Mann M. Plasma exchange (PE) and lymphocytapheresis (LCA) in multiple sclerosis (MS). Int J Artif Organs 1984;7:39–42.

    PubMed  Google Scholar 

  46. Trouillas P, Neuschwander PH, Tremisi JP. Modification rapide par les échanges plasmatiques de la semiologie de formes progressive de la sclérose en plaques. Rev Neurol (Paris) 1986;142:689–95.

    CAS  Google Scholar 

  47. Trouillas P, Neuschwander Ph, Nighoghossian N, et al. Heavy immunosuppressive treatment in progressive multiple sclerosis: A three-arm study concerning cyclophosphamide, cyclophosphamide and plasmapheresis and controls. Results after three years. In: Confavreaux X, Aimard G, Devic M (eds). Trends in European multiple sclerosis research. New York: Elsevier Science Publishers (Biomedical Division) 1988:351–9.

    Google Scholar 

  48. Bystryn JC, Shenkein I, Uhr JW. A model for the regulation of antibody synthesis by serum antibody. In: Amos B (ed). Progress in immunology. New York: Academic Press, 1971:627–37.

    Google Scholar 

  49. Weiner HL, Dau P, Khatri BO, et al. Double-blind study of true versus sham plasma exchange in patients being treated with immunosuppresion for acute attacks of multiple sclerosis. Neurology 1989;39:1143–9.

    Article  CAS  PubMed  Google Scholar 

  50. Barnes MP, Bateman DE, Cleland PG, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiat 1985; 48:157–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Ellison GW, Meyers LW. A review of systemic non- specific immunosuppressive treatment of multiple sclerosis. Neurology 1978;28:132–9.

    Article  CAS  PubMed  Google Scholar 

  52. Kaplan SR, Calabresi P. Drug therapy immunosuppressive agents (second of two parts). N Engl J Med 1973:1234–6.

    Google Scholar 

Download references

Authors
  1. B. O. Khatri
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank Groningen-Drenthe, The Netherlands

    C. Th. Smit Sibinga

  2. University Hospital Utrecht, The Netherlands

    L. Kater

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Khatri, B.O. (1991). Plasmapheresis in Neurological Disorder. In: Sibinga, C.T.S., Kater, L. (eds) Advances in haemapheresis. Developments in Hematology and Immunology, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3904-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3904-9_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6742-0

  • Online ISBN: 978-1-4615-3904-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation